Compare Novavax Inc (NVAX) vs Seagate Technology Holdings PLC (STX) Price & Performance

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.

Seagate Technology (STX) trades at $774.83, down 4.03% amid concerns about increased competition from Toshiba's planned hard drive production expansion. The stock shows strong fundamental performance with Q2 2026 EPS of $5.71 beating expectations by 12%, and robust profitability metrics including 26.11% net income margin and 371.53% ROE. Technical indicators signal bearish momentum with price below key pivot points, though RSI suggests potential oversold conditions. Analyst consensus remains positive with 54% buy ratings and $1,130 price target representing 46% upside potential.

STX presents a compelling growth story driven by AI storage demand, but faces near-term headwinds from competitive threats. The company's strong earnings beat streak and projected 2026 revenue growth to $12.2B support long-term optimism, while current valuation multiples appear elevated. Key risks include pricing pressure from new capacity and dependency on AI infrastructure spending cycles.